Literature DB >> 2189594

Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer.

H Kühnle1, H G Meerpohl, W Eiermann, S Röben, L Lenaz, W Achterrath.   

Abstract

A total of 32 patients with advanced squamous-cell carcinoma of the cervix were treated with 300 mg/m2 i.v. carboplatin and 5 g/m2 ifosfamide as a 24-h i.v. infusion, both given on day 1 every 4 weeks. In all, 3 (9%) complete responses (CRs) and 19 (59%) objective responses (CR + PR) were achieved in 32 patients. Myelosuppression with leukopenia and/or thrombocytopenia of WHO grade 4 in 28% and 13% of patients, respectively, was the main toxicity. The results of our study suggest that carboplatin/ifosfamide is active as neoadjuvant treatment in advanced cervical cancer.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2189594     DOI： 10.1007/bf00685414

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  7 in total

1.  Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer.

Authors:  E J Buxton; C A Meanwell; C Hilton; J J Mould; D Spooner; A Chetiyawardana; T Latief; M Paterson; C W Redman; D M Luesley
Journal:  J Natl Cancer Inst       Date:  1989-03-01       Impact factor: 13.506

2.  Phase II study of ifosfamide in cervical cancer.

Authors:  C A Meanwell; J J Mould; G Blackledge; F G Lawton; N S Stuart; J Kavanagh; T N Latief; D Spooner; A D Chetiyawardana
Journal:  Cancer Treat Rep       Date:  1986-06

3.  Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.

Authors:  P Bonomi; J A Blessing; F B Stehman; P J DiSaia; L Walton; F J Major
Journal:  J Clin Oncol       Date:  1985-08       Impact factor: 44.544

4.  A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study.

Authors:  J T Thigpen; J A Blessing; P J DiSaia; W C Fowler; K D Hatch
Journal:  Gynecol Oncol       Date:  1989-02       Impact factor: 5.482

5.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

6.  A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix.

Authors:  R E Coleman; P G Harper; C Gallagher; R Osborne; E M Rankin; A C Silverstone; M L Slevin; R L Souhami; J S Tobias; C W Trask
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  The prognostic value of a response to chemotherapy given before radiotherapy in advanced cancer of cervix.

Authors:  R P Symonds; R A Burnett; T Habeshaw; S B Kaye; M P Snee; E R Watson
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640
  7 in total
  3 in total

Review 1.  Chemotherapy for advanced or recurrent carcinoma of the cervix.

Authors:  J D Bloss
Journal:  Curr Oncol Rep       Date:  2001-01       Impact factor: 5.075

Review 2.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 3.  Dosing and side-effects of ifosfamide plus mesna.

Authors:  W P Brade; K Herdrich; U Kachel-Fischer; C E Araujo
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.